StudyCor Oy
- Address
- lock Available on a paid plan
Cardiovascular Diseases
StudyCor Oy in Jyvaskyla is involved in research focused on cardiovascular diseases, especially atherosclerotic cardiovascular disease, high cardiovascular risk, and heart failure. These trials are designed to evaluate new ways to lower the risk of serious events such as heart attack, stroke, and cardiovascular death.
- Testing treatments aimed at reducing major cardiovascular events in people with established vascular disease
- Studying options for patients at high risk of heart disease without a prior heart attack or stroke
- Evaluating therapies for heart failure and related kidney impairment
The research also includes people with hypertension and broader cardiovascular disease, reflecting a strong interest in improving long-term protection and treatment effectiveness.
Digestive System Diseases
The site is also conducting studies in digestive system diseases, with a main focus on celiac disease. This research looks at whether new treatment approaches can ease ongoing symptoms and support better disease control in people who continue to feel unwell despite following a gluten-free diet.
- Assessing symptom improvement in celiac disease
- Exploring treatments for patients with mucosal damage despite dietary management
- Supporting better understanding of persistent digestive symptoms
These trials aim to improve day-to-day quality of life for people living with chronic intestinal inflammation and food-related sensitivity.
Nutritional and Metabolic Diseases
Research at StudyCor Oy also covers nutritional and metabolic diseases, including type 2 diabetes, obesity, and related cardiovascular-metabolic conditions. The studies are examining whether new treatment combinations can better reduce cardiovascular risk in people with overlapping metabolic and heart disease.
- Investigating therapies for type 2 diabetes with established cardiovascular disease
- Studying approaches for people with overweight or obesity and atherosclerotic cardiovascular disease
- Evaluating treatment strategies that address both metabolic health and heart protection
This area of research reflects a growing effort to manage linked conditions more effectively, especially when diabetes, blood pressure, weight, and cardiovascular risk occur together.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in StudyCor Oy
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| BI 456906 | 2 | Unknown | 2024-01-08 | 2024-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.